News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celtaxsys, Inc. Appoints Khalil Barrage to Board of Directors


4/19/2013 7:46:33 AM

Celtaxsys Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced that Mr. Khalil Barrage has been appointed to the Board of Directors.

“As a as a major healthcare investor, Khalil brings a depth of experience and expertise to our leadership team. We are pleased that he has chosen to join Celtaxsys as the Company moves its lead compound, CTX-4430, through clinical development,” said Dr. Michael R. Hanley, CEO and Chairman.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES